Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company, which develops, manufactures and markets electrosurgical tools used in operating rooms.
JNJ’s three-month share price movement shows that the stock has outperformed the Zacks classified Large Cap Pharma industry. Specifically, the company gained 0.5%, while the industry lost 2%.
The acquisition brings together the intelligence of Ethicon's advanced energy devices with Megadyne's portfolio of electrosurgical tools, thereby strengthening the J&J’s Medical Device segment.
Per the company’s press release, electrosurgical devices are used in nearly four out of every five surgeries. Hence, the acquisition of Megadyne is expected to boost Ethicon's presence in the multi-billion dollar global energy market. This would in turn provide significant value to hospital systems and surgeons, and also help out in reaching more patients worldwide.
We note that J&J has always been active in terms of acquisitions, as a part of its expansion strategy. Also, it has struck several deals, which should enable the company to boost its top line. Presently, within the Medical Devices segment, J&J continues to look for bolt-on acquisitions in orthopedics and general surgery. When asked about its acquisition strategy for the Medical Device segment at the third-quarter conference call, management specified certain areas like structural heart to look attractive in the cardiovascular segment.
The company has made regular acquisition and deal in the pharma segment as well. The Cougar Biotechnology acquisition in May 2009, allowed J&J to strengthen its oncology portfolio, especially in the areas of advanced prostate cancer, breast cancer and multiple myeloma. The Aragon acquisition in Aug 2012, led toward adding its lead pipeline candidate, JNJ-927 (apalutamide), to J&J's pipeline. JNJ-927 (apalutamide) is presently in late-stage development for pre-metastatic prostate cancer (CRPC), Additionally, Johnson & Johnson signed a deal with Achillion Pharmaceuticals, Inc. for the development of hepatitis C virus (HCV) candidates.
In Sep 2016, J&J announced plans to acquire Abbott’s vision care business’s Abbott Medical Optics for $4.325 billion. The acquisition is expected to close in the first quarter of 2017. Moreover, in Nov 16, J&J had also approached Swiss biotechnology company, Actelion Ltd. , with a potential takeover offer. Actelion is a leader in the pulmonary arterial hypertension (PAH) market with key drugs like Opsumit, Tracleer, Ventavis, Veletri and Uptravi.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company, which develops, manufactures and markets electrosurgical tools used in operating rooms.
JNJ’s three-month share price movement shows that the stock has outperformed the Zacks classified Large Cap Pharma industry. Specifically, the company gained 0.5%, while the industry lost 2%.
The acquisition brings together the intelligence of Ethicon's advanced energy devices with Megadyne's portfolio of electrosurgical tools, thereby strengthening the J&J’s Medical Device segment.
Per the company’s press release, electrosurgical devices are used in nearly four out of every five surgeries. Hence, the acquisition of Megadyne is expected to boost Ethicon's presence in the multi-billion dollar global energy market. This would in turn provide significant value to hospital systems and surgeons, and also help out in reaching more patients worldwide.
We note that J&J has always been active in terms of acquisitions, as a part of its expansion strategy. Also, it has struck several deals, which should enable the company to boost its top line. Presently, within the Medical Devices segment, J&J continues to look for bolt-on acquisitions in orthopedics and general surgery. When asked about its acquisition strategy for the Medical Device segment at the third-quarter conference call, management specified certain areas like structural heart to look attractive in the cardiovascular segment.
The company has made regular acquisition and deal in the pharma segment as well. The Cougar Biotechnology acquisition in May 2009, allowed J&J to strengthen its oncology portfolio, especially in the areas of advanced prostate cancer, breast cancer and multiple myeloma. The Aragon acquisition in Aug 2012, led toward adding its lead pipeline candidate, JNJ-927 (apalutamide), to J&J's pipeline. JNJ-927 (apalutamide) is presently in late-stage development for pre-metastatic prostate cancer (CRPC), Additionally, Johnson & Johnson signed a deal with Achillion Pharmaceuticals, Inc. for the development of hepatitis C virus (HCV) candidates.
In Sep 2016, J&J announced plans to acquire Abbott’s vision care business’s Abbott Medical Optics for $4.325 billion. The acquisition is expected to close in the first quarter of 2017. Moreover, in Nov 16, J&J had also approached Swiss biotechnology company, Actelion Ltd. , with a potential takeover offer. Actelion is a leader in the pulmonary arterial hypertension (PAH) market with key drugs like Opsumit, Tracleer, Ventavis, Veletri and Uptravi.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on JNJ - FREE
Get the latest research report on ENZ - FREE